pharma · COVID-19 · Hepatitis C · AVIR
Atea Pharmaceuticals
Atea Pharmaceuticals trial registry — 40 ClinicalTrials.gov studies with program phase, status, and indication context.
Company details
- Status
- Public
- HQ
- 225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US
- Founded
- 2014
- Employees
- 57
- Programs
- 37
- Drugs
- 29
- Patents
- 35
Atea Pharmaceuticals clinical trials
Registry index of 40 ClinicalTrials.gov studies linked to Atea Pharmaceuticals programs — each row shows trial ID, program name, phase, status, and indication.
Atea Pharmaceuticals trial registry — 40 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Atea Pharmaceuticals.
-
AT-01B-008 — Phase 3
Clinical update -
AT-01B-006 — Phase 1
Clinical update -
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting — Phase 1
Clinical update -
GHB04L1 — Phase 1
Clinical update -
Ethinyl Estradioll/Levonorgestrel (EE/LNG) — Phase 1
Clinical update -
Buprenorphine/Naloxone + BEM/RZR — Phase 1
Clinical update -
Bemnifosbuvir (BEM) — Phase 3
Clinical update -
Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions — Phase 1
Clinical update
Trial registry
-
CTIS ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT05629962CT.gov ↗
Bemnifosbuvir (BEM)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗